Clinical Trials

Find trials

Perform a New Search

Search Results 1851-1860 of 2905 for cancer

Edit search filters

Study Of Pembrolizumab (MK-3475) Compared To Platinum-Based Chemotherapies In Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Rochester, MN
- See Details
Study Of Pembrolizumab (MK-3475) Compared To Platinum-Based Chemotherapies In Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  3
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

This is an efficacy and safety study to assess pembrolizumab (MK-3475/SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) strong expressing Non-Small Cell Lung Cancer (NSCLC). The primary hypothesis of this study is that participants with PD-L1 strong NSCLC will have a longer Progression Free Survival (PFS), as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) when treated with pembrolizumab than when treated with platinum-based chemotherapies.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, MN

Closed for enrollment
View complete study & contact information

Print study details
Site IRB:
14-004369

NCT ID:
NCT02142738

Sponsor Protocol Number:
MK-3475-024
Targeted Treatment For Advanced Non-Small Cell Lung Cancer That Has Increased Copies Of The MET Gene (An Expanded Lung-MAP Treatment Trial)

Jacksonville, FL, Rochester, MN
- See Details
Targeted Treatment For Advanced Non-Small Cell Lung Cancer That Has Increased Copies Of The MET Gene (An Expanded Lung-MAP Treatment Trial)
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  2
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, FL

Open for enrollment
View complete study & contact information

Rochester, MN

Open for enrollment

Print study details
Site IRB:
26-008299

NCT ID:
NCT06116682

Sponsor Protocol Number:
S1900J

Mayo Clinic Location	Status	Contact
Rochester, MN	Closed for enrollment	View complete study & contact information

Mayo Clinic Location	Status	Contact
Jacksonville, FL	Open for enrollment	View complete study & contact information
Rochester, MN	Open for enrollment

Testing The Addition Of High Dose, Targeted Radiation To The Usual Treatment For Locally-Advanced Inoperable Non-small Cell Lung Cancer

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

Testing The Addition Of High Dose, Targeted Radiation To The Usual Treatment For Locally-Advanced Inoperable Non-small Cell Lung Cancer

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
3
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to compare the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Open for enrollment	View complete study & contact information
Jacksonville, FL	Open for enrollment
Rochester, MN	Closed for enrollment

Print study details

Site IRB:
24-001802
NCT ID:
NCT05624996
Sponsor Protocol Number:
NRG-LU008

Mayo Clinic Location	Status	Contact
Rochester, MN	Closed for enrollment	View complete study & contact information

Mayo Clinic Location	Status	Contact
Rochester, MN	Closed for enrollment	View complete study & contact information

Mayo Clinic Location	Status	Contact
Rochester, MN	Closed for enrollment	View complete study & contact information

Mayo Clinic Location	Status	Contact
Jacksonville, FL	Closed for enrollment	View complete study & contact information

A Study For Women Who Have Platinum Resistant Ovarian Cancer To Evaluate EC145 Combined With Pegylated Liposomal Doxorubicin, Compared To Pegylated Liposomal Doxorubicin Alone

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Study For Women Who Have Platinum Resistant Ovarian Cancer To Evaluate EC145 Combined With Pegylated Liposomal Doxorubicin, Compared To Pegylated Liposomal Doxorubicin Alone

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
3
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to compare the progression-free survival in women who have platinum-resistant ovarian cancer, who receive combination therapy with EC145 and pegylated liposomal doxorubicin (EC145+PLD) with those who receive PLD alone.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Closed for enrollment	View complete study & contact information
Jacksonville, FL	Closed for enrollment
Rochester, MN	Closed for enrollment

Print study details

Site IRB:
10-005707
NCT ID:
NCT01170650
Sponsor Protocol Number:
EC-FV-06

Assessment Of The Efficacy And Safety Of Olaparib Monotherapy Versus Physicians Choice Chemotherapy In The Treatment Of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Jacksonville, FL, Rochester, MN
- See Details
Assessment Of The Efficacy And Safety Of Olaparib Monotherapy Versus Physicians Choice Chemotherapy In The Treatment Of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  3
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, FL

Closed for enrollment
View complete study & contact information

Rochester, MN

Closed for enrollment

Print study details
Site IRB:
14-001087

NCT ID:
NCT02000622

Sponsor Protocol Number:
D0819C00003

Mayo Clinic Location	Status	Contact
Jacksonville, FL	Closed for enrollment	View complete study & contact information
Rochester, MN	Closed for enrollment

Pagination Clinical studies

Clinical Trials

Filter Results

Locations

Study status

Gender

Age

Healthy Volunteer

Study phase

Search Results 1851-1860 of 2905 for cancer

Study Of Pembrolizumab (MK-3475) Compared To Platinum-Based Chemotherapies In Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Targeted Treatment For Advanced Non-Small Cell Lung Cancer That Has Increased Copies Of The MET Gene (An Expanded Lung-MAP Treatment Trial)

Testing The Addition Of High Dose, Targeted Radiation To The Usual Treatment For Locally-Advanced Inoperable Non-small Cell Lung Cancer

A Study Of ASP8273 Versus Erlotinib Or Gefitinib As First-Line Treatment For Patients With Stage IIIB/IV Non-Small Cell Lung Cancer

A Study Of Pembrolizumab Alone Or Combined With CC-486 For Patients With Platinum-Resistant Ovarian, Fallopian Tube, Or Peritoneal Cancer

Phase II Trial Of Irinotecan, Cetuximab, And Bevacizumab Compared With Irinotecan, Cetuximab, And Placebo In KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer

A Randomized, Double-blind, Phase 3 Efficacy Trial Of PROSTVAC-V/F +/- GM-CSF In Men With Asymptomatic Or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

A Study To Evaluate Treating Post-Mastectomy Radiation Injury In Breast Cancer Patients With Adipose-Induced Regeneration Of Breast Skin (AIR Breast)

A Study For Women Who Have Platinum Resistant Ovarian Cancer To Evaluate EC145 Combined With Pegylated Liposomal Doxorubicin, Compared To Pegylated Liposomal Doxorubicin Alone

Assessment Of The Efficacy And Safety Of Olaparib Monotherapy Versus Physicians Choice Chemotherapy In The Treatment Of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Mayo Clinic Footer

Legal Conditions and Terms

Advertising

Reprint Permissions